Kinetics of B, T, NK lymphocytes and isoagglutinin titers in ABO incompatible living donor liver transplantation using rituximab and basiliximab

Transplant Immunology

Volumn 32, Issue 1, 2015, Pages 29-34

  Lee, Seung Duk ^a   Kim, Seong Hoon ^a   Kong, Sun Young ^a   Kim, Young Kyu ^b   Park, Sang Jae ^a  

^a National Cancer Center   (South Korea)

^b Kangwon National University   (South Korea)

Author keywords

ABO incompatible; Basiliximab; Kinetics; Living donor liver transplantation; Rituximab

Indexed keywords

AGGLUTININ; BASILIXIMAB; CD16 ANTIGEN; CD19 ANTIGEN; CD56 ANTIGEN; IMMUNOGLOBULIN; RITUXIMAB; BLOOD GROUP ABO SYSTEM; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY MEDIATED REJECTION; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BLOOD GROUP ABO INCOMPATIBILITY; CANCER RECURRENCE; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; FEMALE; HUMAN; HUMAN CELL; HYPERACUTE GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONOR; MALE; NATURAL KILLER CELL; PLASMAPHERESIS; POSTOPERATIVE PERIOD; SINGLE DRUG DOSE; T LYMPHOCYTE; TREATMENT OUTCOME; BLOOD; BLOOD GROUP ABO SYSTEM; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; IMMUNOLOGY; KINETICS; LIVER NEOPLASMS; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED;

ABO BLOOD-GROUP SYSTEM; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; KINETICS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PLASMA EXCHANGE; RECOMBINANT FUSION PROTEINS;

EID: 84920469680     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2014.11.216     Document Type: Article

References (35)

1. Chen C.L., Fan S.T., Lee S.G., Makuuchi M., Tanaka K. Living-donor liver transplantation: 12years of experience in Asia. Transplantation 2003, 75:S6-S11.
2. Gugenheim J., Samuel D., Reynes M., Bismuth H. Liver transplantation across ABO blood group barriers. Lancet 1990, 336:519-523.
3. Farges O., Kalil A.N., Samuel D., Saliba F., Arulnaden J.L., Debat P., et al. The use of ABO-incompatible grafts in liver transplantation: a life-saving procedure in highly selected patients. Transplantation 1995, 59:1124-1133.
4. Lo C.M., Shaked A., Busuttil R.W. Risk factors for liver transplantation across the ABO barrier. Transplantation 1994, 58:543-547.
5. Urbani L., Mazzoni A., Bianco I., Grazzini T., De Simone P., Catalano G., et al. The role of immunomodulation in ABO-incompatible adult liver transplant recipients. J Clin Apher 2008, 23:55-62.
6. Ikegami T., Taketomi A., Soejima Y., Yoshizumi T., Uchiyama H., Harada N., et al. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation. Transplantation 2009, 88:303-307.
7. Egawa H., Teramukai S., Haga H., Tanabe M., Fukushima M., Shimazu M. Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology 2008, 47:143-152.
8. Raut V., Mori A., Kaido T., Ogura Y., Taku I., Nagai K., et al. Splenectomy does not offer immunological benefits in ABO-incompatible liver transplantation with a preoperative rituximab. Transplantation 2012, 93:99-105.
9. Tanabe M., Kawachi S., Obara H., Shinoda M., Hibi T., Kitagawa Y., et al. Current progress in ABO-incompatible liver transplantation. Eur J Clin Investig 2010, 40:943-949.
10. Soejima Y., Muto J., Matono R., Ninomiya M., Ikeda T., Yoshizumi T., et al. Strategic breakthrough in adult ABO-incompatible living donor liver transplantation: preliminary results of consecutive seven cases. Clin Transpl 2013, 27(2):227-231.
11. Egawa H., Teramukai S., Haga H., Tanabe M., Mori A., Ikegami T., et al. Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: a Japanese multicenter study. Am J Transplant 2014, 14:102-114.
12. Uchiyama H., Mano Y., Taketomi A., Soejima Y., Yoshizumi T., Ikegami T., et al. Kinetics of anti-blood type isoagglutinin titers and B lymphocytes in ABO-incompatible living donor liver transplantation with rituximab and plasma exchange. Transplantation 2011, 92:1134-1139.
13. Meyer E.A., Shulman I.A. The sensitivity and specificity of the immediate-spin crossmatch. Transfusion 1989, 29:99-102.
14. Rego J., Prevost F., Rumeau J.L., Modesto A., Fourtanier G., Durand D., et al. Hyperacute rejection after ABO-incompatible orthotopic liver transplantation. Transplant Proc 1987, 19:4589-4590.
15. Sanchez-Urdazpal L., Sterioff S., Janes C., Schwerman L., Rosen C., Krom R.A. Increased bile duct complications in ABO incompatible liver transplant recipients. Transplant Proc 1991, 23:1440-1441.
16. Stewart Z.A., Locke J.E., Montgomery R.A., Singer A.L., Cameron A.M., Segev D.L. ABO-incompatible deceased donor liver transplantation in the United States: a national registry analysis. Liver Transpl 2009, 15:883-893.
17. Demetris A.J., Jaffe R., Tzakis A., Ramsey G., Todo S., Belle S., et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol 1988, 132:489-502.
18. Monteiro I., McLoughlin L.M., Fisher A., de la Torre A.N., Koneru B. Rituximab with plasmapheresis and splenectomy in ABO-incompatible liver transplantation. Transplantation 2003, 76:1648-1649.
19. Usuda M., Fujimori K., Koyamada N., Fukumori T., Sekiguchi S., Kawagishi N., et al. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation 2005, 79:12-16.
20. Egawa H., Ohmori K., Haga H., Tsuji H., Yurugi K., Miyagawa-Hayashino A., et al. B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation. Liver Transpl 2007, 13:579-588.
21. Saito K., Nakagawa Y., Suwa M., Kumagai N., Tanikawa T., Nishiyama T., et al. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplantation 2006, 13:111-117.
22. Weiner G.J. Rituximab: mechanism of action. Semin Hematol 2010, 47:115-123.
23. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
24. Mok C.C. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Dev Ther 2013, 8:87-100.
25. Cai J., Terasaki P.I. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation 2010, 90:1511-1515.
26. Rostaing L., Saliba F., Calmus Y., Dharancy S., Boillot O. Review article: use of induction therapy in liver transplantation. Transplant Rev 2012, 26:246-260.
27. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
28. Tian Z., Chen Y., Gao B. Natural killer cells in liver disease. Hepatology 2013, 57:1654-1662.
29. Moroso V., Metselaar H.J., Mancham S., Tilanus H.W., Eissens D., van der Meer A., et al. Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation. Liver Transpl 2010, 16:895-908.
30. Anfossi N., Andre P., Guia S., Falk C.S., Roetynck S., Stewart C.A., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006, 25:331-342.
31. Golden-Mason L., Cox A.L., Randall J.A., Cheng L., Rosen H.R. Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology 2010, 52:1581-1589.
32. Vermijlen D., Luo D., Froelich C.J., Medema J.P., Kummer J.A., Willems E., et al. Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. J Leukoc Biol 2002, 72:668-676.
33. Jacobson I.M., Gordon S.C., Kowdley K.V., Yoshida E.M., Rodriguez-Torres M., Sulkowski M.S., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013, 368:1867-1877.
34. Takahashi K. A new concept of accommodation in ABO-incompatible kidney transplantation. Clin Transpl 2005, 19(Suppl. 14):76-85.
35. Takahashi K., Saito K. ABO-incompatible kidney transplantation. Transplant Rev 2013, 27:1-8.